Clal Biotechnology Industries Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Assaf Segal
Chief executive officer
₪1.7m
Total compensation
| CEO salary percentage | 73.9% |
| CEO tenure | 1.9yrs |
| CEO ownership | n/a |
| Management average tenure | 2.3yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
The Market Doesn't Like What It Sees From Clal Biotechnology Industries Ltd.'s (TLV:CBI) Revenues Yet
Apr 18
Calculating The Fair Value Of Clal Biotechnology Industries Ltd. (TLV:CBI)
Jul 14Does Clal Biotechnology Industries (TLV:CBI) Have A Healthy Balance Sheet?
Jan 19Investors Shouldn't Be Too Comfortable With Clal Biotechnology Industries' (TLV:CBI) Robust Earnings
Mar 25Clal Biotechnology Industries (TLV:CBI) Seems To Use Debt Quite Sensibly
Mar 24Introducing Clal Biotechnology Industries (TLV:CBI), The Stock That Zoomed 121% In The Last Year
Feb 16
What Kind Of Shareholders Own Clal Biotechnology Industries Ltd. (TLV:CBI)?
Jan 12Is Clal Biotechnology Industries (TLV:CBI) Using Too Much Debt?
Dec 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -₪31m |
| Sep 30 2023 | n/a | n/a | -₪20m |
| Jun 30 2023 | n/a | n/a | -₪6m |
| Mar 31 2023 | n/a | n/a | -₪7m |
| Dec 31 2022 | ₪2m | ₪1m | -₪7m |
| Sep 30 2022 | n/a | n/a | -₪78m |
| Jun 30 2022 | n/a | n/a | -₪18m |
| Mar 31 2022 | n/a | n/a | -₪86m |
| Dec 31 2021 | ₪2m | ₪1m | -₪28m |
| Sep 30 2021 | n/a | n/a | ₪103m |
| Jun 30 2021 | n/a | n/a | ₪89m |
| Mar 31 2021 | n/a | n/a | ₪109m |
| Dec 31 2020 | ₪1m | ₪1m | ₪186m |
| Sep 30 2020 | n/a | n/a | -₪41m |
| Jun 30 2020 | n/a | n/a | -₪51m |
| Mar 31 2020 | n/a | n/a | -₪144m |
| Dec 31 2019 | ₪2m | ₪1m | -₪154m |
Compensation vs Market: Assaf's total compensation ($USD467.16K) is about average for companies of similar size in the IL market ($USD442.79K).
Compensation vs Earnings: Assaf's compensation has increased whilst the company is unprofitable.
CEO
Assaf Segal
1.9yrs
Tenure
₪1,715,000
Compensation
Mr. Assaf Segal is Acting Chief Executive Officer of Clal Biotechnology Industries Ltd. He was Chief Executive Officer of Clal Biotechnology Industries Ltd. Since November 2022.He served as the Acting Chi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting Chief Executive Officer | 1.9yrs | ₪1.72m | no data | |
| Vice President of Finance | 2.3yrs | ₪225.00k | no data | |
| Vice President of Research & Development - MediWound | no data | ₪1.10m | no data | |
| Vice President of Medical Technologies - MediWound | no data | ₪1.21m | no data | |
| Accountant | 2.3yrs | no data | no data | |
| General Counsel & Corporate Secretary | no data | no data | no data | |
| Medical Director | 2.3yrs | no data | no data |
2.3yrs
Average Tenure
54yo
Average Age
Experienced Management: CBI's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| External Independent Director | 8.4yrs | no data | no data | |
| Independent External Director | 4.3yrs | no data | no data | |
| Chairman | 21yrs | no data | no data | |
| Director | 21.2yrs | no data | no data | |
| Director | 6.5yrs | no data | no data | |
| Director | 6.4yrs | no data | no data |
7.5yrs
Average Tenure
69yo
Average Age
Experienced Board: CBI's board of directors are considered experienced (7.5 years average tenure).